What will it take to end the crisis of Black deaths in the U.S.?
In the last two decades, Black Americans have suffered 1.63 million excess deaths compared to…
Category: Medicine
STAT+: Health tech investors are getting selective. Expect slow growth, consolidation
Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to…
Opinion: Done right, AI can give patients crucial information on the quality of their care
Almost as soon as ChatGPT was released to the public, doctors began focusing on how…
Meghan O’Rourke on a medical system not built for chronic illness — and the ‘invisible kingdom’ that could spur change
When her life was upturned by an accumulating array of confounding health problems, Meghan O’Rourke…
STAT+: UnitedHealth discontinues a controversial brand amid scrutiny of algorithmic care denials
UnitedHealth Group and Optum are getting rid of the name of their tech-driven care management…
STAT+: Roche buys Telavant from Roivant for $7 billion, gaining bowel disease drug candidate
Roche said Monday it was buying Telavant Holdings for $7.1 billion upfront, picking up a…
STAT+: Roche drug slashes recurrence, death risk in lung cancer that afflicts younger patients
MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus…
.jpg)
STAT+: Eli Lilly, riding a hot streak, expects to double planned employment in Boston research center
Eli Lilly and Co., which transformed itself from a stodgy underperformer into one of the…
How an ER doctor in Chicago is tackling trauma from gun violence
Abdullah Pratt was only ever interested in science and in sports because of his older…
Why Biogen is purposefully becoming more risk averse, according to Biogen’s CEO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: China arrests an Astellas exec accused of spying; weight-loss drugs are being tested in children
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Lilly complains to the U.S. International Trade Commission about unapproved versions of Mounjaro
As demand for weight-loss treatments intensifies, Eli Lilly has filed a complaint with the U.S….
STAT+: Study on Amgen’s ‘bispecific’ immunotherapy could lead to approval in small cell lung cancer
MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients…
Opinion: STAT+: How to make the EU’s new Joint Clinical Assessment process work for industry — and for patients
Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices…
Dobbs decision leaving broad imprint on reproductive medicine
NEW ORLEANS — The annual meeting of the American Society of Reproductive Medicine is usually…
Doctor vs. ChatGPT showed promise and blind spots of generative AI
Generative AI tools, also known as large language models, are already helping doctors transcribe visits…
Researchers try to tease out possible ties between long Covid and menopause
When she stopped getting her period in March 2022, Daryn Schwartz wasn’t especially concerned. At…
STAT+: Pharmacists can make shortage drugs, but at what cost?
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in…
STAT+: How biotech deal-making really works behind the scenes, according to founders
What does it feel like to run a biotech startup and then get “the call”…
STAT+: After a lull, the pace of FDA authorization of AI-enabled medical devices is rising
The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools…
STAT+: Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion
MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a…
STAT+: HHS leader on health and climate change talks health sector emissions and heat emergencies
Renee Salas, an emergency medicine physician at Massachusetts General Hospital, blames climate change for the…
STAT+: House committee hearing kicks off potential doctor pay reforms in Medicare
WASHINGTON — The House Energy & Commerce health subcommittee kicked off its first hearing in…
STAT+: GSK CEO on pharma giant’s new direction: ‘We’re in the business of preventing and treating disease’
The story of GSK is one of reinvention, CEO Emma Walmsley said at the STAT…
Michael J. Fox on how far Parkinson’s research has come: “We don’t want to be celebrated. We want to get things done.”
When Michael J. Fox was diagnosed with Parkinson’s disease at age 29, his clearest symptom…
STAT+: The future of Biogen: Pragmatism, ‘a few moonshots,’ and no Twinkies
Two years after a big scientific swing nearly pushed Biogen to the brink, CEO Christopher…
Listen: Live from the 2023 STAT Summit
What if CRISPR isn’t all that commercial? How does the NurOwn story end? And how…
STAT+: Zuckerberg and Chan on track to put $50 billion toward science: ‘That’s the trajectory we’re on’
Mark Zuckerberg and Priscilla Chan sit atop a fortune that is currently valued at $113…
STAT+: Actually, hospital price transparency does save money, advocate highlights
BOSTON — For all those who think hospital price transparency will not save money, Cynthia…
STAT+: Startup Laronde merges with another biotech in wake of data integrity issue
RNA medicines startup Laronde is merging with another startup in the wake of a scientific…
STAT+: Beam Therapeutics to lay off 20% of its staff, reevaluate programs as it cuts costs
Beam Therapeutics said Monday morning it would lay off 20% of its staff — or…
What if there’s no market for a CRISPR cure?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Pfizer prices Paxlovid at $1,400 for a five-day course; EMA warns of counterfeit Ozempic
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
Opinion: A better way for doctors and health plans to manage genetic tests
New technology has a history of overwhelming existing systems that try to manage it, and…
STAT+: A 50-year battle over one additive highlights FDA’s challenges with food safety
WASHINGTON — Richard Nixon was the president when the Food and Drug Administration issued its…
Older adults are vulnerable in a warming climate. Better buildings could help protect them
In 2003, during Europe’s worst heat wave in centuries, almost 15,000 people died in France….
STAT+: What to watch at ESMO: readouts from trials in lung, prostate, and other types of cancer
Europe’s major cancer research conference kicks off in Madrid on Friday, with headline — and…
STAT+: Dana-Farber executive says split from Mass General will benefit patients
Laurie Glimcher trained at Massachusetts General Hospital. Her father was the chair of orthopedic surgery…
STAT+: Senate Finance targets Medicare Advantage brokers
Senate Finance Committee members from both parties took aim today at insurance brokers that sell…
STAT+: Biotech power broker John Maraganore offers advice to the next crop of entrepreneurs
During a nearly two-decade stint as Alnylam’s founding CEO, John Maraganore took a promising but…
How rising stars in science and medicine think about mentorship and bouncing back from rejection
At the age of 26, Lauren Ghazal was diagnosed with Hodgkin’s lymphoma just months into…
.jpg)
Zuckerberg and Chan announce a New York biohub to build disease-fighting cellular machines
Meta founder Mark Zuckerberg and his wife, pediatrician and philanthropist Priscilla Chan, will announce on…
Lotte Knudsen, who pushed Novo Nordisk into the Ozempic era, wins STAT Innovation award
Back in the 1990s, scientist Lotte Bjerre Knudsen was tasked with revitalizing a floundering program…
STAT+: NIH confirmation hearing highlights just how divisive the agency’s portfolio has become
Monica Bertagnolli, President Biden’s nominee to lead the National Institutes of Health, spent her confirmation…
STAT+: In drug development, large pharma companies’ staying power provides them an edge, Lilly’s chief medical officer says
Among drugmakers, big pharma has a reputation of being stodgy and old-fashioned, while biotech startups…
STAT+: Biotech investors push to extend time before pills are subject to price negotiations
The fight over drug prices is far from over. Investors in biopharma companies, who lobbied…
Wegovy doesn’t work for everyone, and no one’s quite sure why
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: Biotech investors push to extend time before Medicare price negotiations; RiteAid closings could cause pharmacy deserts
Good morning, everyone, and how are you today? We are doing just fine, thank you….
STAT+: Why doesn’t everyone lose weight on Ozempic-type drugs? Researchers look for genetic clues
DALLAS — Treatments like Ozempic, Wegovy, and Mounjaro have been hailed for showing 15% to…
STAT+: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic
There’s a specter haunting Wall Street. It started in biotech, where companies making drugs for…